摘要
目的:探讨服用血脂康对中国人群冠心病二级预防的效果。方法:随机双盲法把100例心肌梗死后的冠心病患者分为血脂康研究组及安慰剂对照组,观察3～5年血脂变化、临床理化指标及冠心病事件、冠心病死亡、总死亡及对冠脉内支架术(PICA)、冠脉旁路移植术(CABG)的需求量。结果:血脂康组调脂治疗后明显降低TC 17％,降低LDL-C29％,降低TG7％,提高HDL-C 8％;同时临床终点事件明显改观,再发冠心病事件减少15.6％,冠心病死亡减少7.7％,总死亡减少9.6％,PTCA及CABG需求减少25.5％,且未见较明显不良反应。结论:血脂康对中国人群中的冠心病二级预防有肯定作用,副作用轻微。
Objective: To explore the Secondary prevention effect of Xuezhikang(XZK) on coronary heart disease(CHD). Meth-
ods: One hundred patients with CHD after myocardial infarction were divided in random double--blind way into groups: XZK treat-
ment and placebo control. The following parameters were monirored within 3 to 5 yeare: blood lipid levels, Clinical manifestation, CHD
events, CHD--related death, total death rate, and requirement for percutaneous coronary artery (PTCA) and stent or coronary artory by
pass graft (CABG). Results: After XZK treatment, TC decreased by 17%, IDL--C 29% and TG 7%, and HDL--C increased by
8%. The difference of treatment effects between two group was significant. Recurrent CHD events decreased by 15. 6%, CHD--related
death 7. 7%, total death rate 9. 6%, and equirment for PTCA and CABG 25. 5% in XZK treatment group. XZK tretment had no obvious
adverse effect. Conclusion: XZK is of secondry prevention effect on CHD in China population, and its adverse effects appear mildLy.
出处
《中国医药导刊》
2004年第3期197-199,共3页
Chinese Journal of Medicinal Guide
基金
北京市朝阳区科委47-QK980204课题
关键词
血脂康
冠心病
二级预防
安全性
调脂药
staitins
Xuezhikang
Lipid-modulating therapy
myocardial infarction
secondary prevention
Coronary heart discase
